



**Patent Office  
Canberra**

I, JULIE BILLINGSLEY, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2003905692 for a patent by CRC FOR INNOVATIVE DAIRY PRODUCTS as filed on 17 October 2003.

WITNESS my hand this  
Twenty-sixth day of October 2004

**JULIE BILLINGSLEY  
TEAM LEADER EXAMINATION  
SUPPORT AND SALES**



**BEST AVAILABLE COPY**

AUSTRALIA  
Patents Act 1990

**PROVISIONAL SPECIFICATION**

**Applicant(s) :**

CRC FOR INNOVATIVE DAIRY PRODUCTS

**Invention Title:**

HIGH DENSITY CULTURE TECHNIQUE

The invention is described in the following statement:

HIGH DENSITY CULTURE TECHNIQUE

FIELD OF THE INVENTION

5 The present invention relates to a method and a media composition for producing primary cell cultures comprising predominantly tissue-specific progenitor cells or stem cell-like cells. In particular, the present invention relates to a method for the isolation and the selective 10 expansion of mesenchymal connective tissue derived stem cell-like cells (MCTs) from tissue biopsies of fetal and adult donors.

BACKGROUND OF THE INVENTION

15 Nuclear transfer techniques typically produce low rates of viable offspring, usually in the range of 0.5-3% of the reconstructed embryos. The efficiency of nuclear transfer techniques has been shown to be partly dependent on the 20 source of donor cells or nuclei. Until the late 1990s it was widely believed that only embryonic or undifferentiated cells or cell nuclei could direct any sort of fetal development in cloning. However, in 1997 Wilmut and co-workers reported successful nuclear transfer 25 experiments using donor cells and nuclei isolated from cultured cell lines (See, eg., Wilmut et al., *Nature* (London) 385, 810-183) (1997).

Recently, it has been demonstrated that nuclei of murine 30 embryonic stem cells are significantly more effective in nuclear transfer with regard to viable offspring per NT-blastocyst than somatic fibroblast and cumulus cells, or terminally differentiated blood cells (30-50% vs. 1-3% vs. <0.03% live cloned offspring) (See, for example, Jaenisch 35 et al. (2002) *Cloning Stem Cells*, 4:389-396 and Hochedlinger & Jaenisch (2002) *Nature*, 415:1035-1038.) Notwithstanding, many laboratories continue to attempt to

develop efficient protocols based on the use of primary fibroblasts in nuclear transfer, because these cells can be easily obtained from tissue biopsies and they proliferate readily in common cell culture media.

5 One of problems with primary fibroblast cultures are that they are a poorly characterised mixture of cell lineages at various stages of development. Moreover, it has been observed that the longer the fibroblasts are in culture 10 the poorer the nuclear transfer efficiency. One possible explanation for this phenomenon is that while primary fibroblast cultures contain a subpopulation of tissue-specific progenitor or stem cells, which have a higher potential to become successfully reprogrammed, these cells 15 are quickly overgrown by the fibroblasts present as existing cell culture techniques do not allow these cells to proliferate.

Consequently, it would be useful to isolate and proliferate 20 the tissue-specific progenitor cells or stem cell-like cells present in the primary cell cultures and use these in a number of procedures including nuclear transfer, targeted differentiation and therapeutic treatments.

25 SUMMARY OF THE INVENTION

The inventors have now surprisingly found a reliable and selective enrichment process, which is capable of producing primary cell cultures comprising predominantly 30 tissue-specific progenitor cells or stem cell-like cells. More importantly, the inventors have also identified unknown mesenchymal connective tissue-derived stem cells (MCT), within the primary cell cultures.

35 Accordingly, a first aspect provides a method for selective culturing of primary cell cultures comprising

culturing tissue biopsies in the presence of at least 25% serum relative to the amount of culture medium. Preferably, the serum is between about 25% to about 70%. More preferably, the serum is between about 30% to about 5 50%. Most preferably, the serum is about 30%.

In one embodiment there is provided a tissue-culture media composition for the selective culturing of primary cell cultures comprising about 30% serum and about 70% culture 10 medium. Preferably, the culture medium is standard tissue culture medium. More preferably, the culture medium is selected from the group consisting of Synthetic Oviductal Fluid (SOF), Modified Eagle's Medium (MEM), Dulbecco's Modified Eagle's Medium (DMEM), RPMI 1640, F-12, IMDM, 15 Alpha Medium and McCoy's Medium. Most preferably, the culture medium is DMEM.

The serum in the culture medium may be allogeneic serum (ie., from the same animal species, but not the same 20 animal), autologous serum (ie., from the same animal) or xenogeneic serum (ie., from a different animal species). Preferably, heat-inactivated autologous serum is used rather than other serum.

25 While the culture medium may simply be a commercially available medium like DMEM, supplemented with at least 30% serum, it is appreciated that other supplements may be included. For example, growth factors, co-factors, salts and antibiotics may be included.

30 In one embodiment, about 50% of the culture medium plus serum is replaced about every 48 hours with fresh medium. Accordingly, a second aspect provides a method for selectively culturing of primary cell cultures comprising: 35 (i) obtaining a tissue biopsy from an animal;

(ii) culturing said tissue biopsy in tissue culture medium comprising at least 25% serum relative; and

5 (iii) replacing about 50% of the culture medium including serum about every 48 hours.

In another embodiment, the tissue biopsies are cultured in the presence of a feeder cell layer. Preferably, the feeder cell layer comprises cultured autologous cells.

10

A third aspect provides an isolated tissue-specific progenitor cell or stem cell-like cell obtained by a method according to the first aspect.

15

Preferably, the tissue-specific progenitor cell or stem cell-like cell is a mesenchymal connective tissue-derived stem cell (MCT). More preferably, the tissue-specific progenitor cell or stem cell-like cell is the mesenchymal connective tissue-derived stem cell (MCT) deposited at the

20

ATCC on December 2003, under accession number #12345

25

The tissue biopsies can be obtained from any animal, including humans. Preferably, the animal is a mammal from the one of the mammalian orders. The mammalian orders include Monotremata, Metatheria, Didelphimorphia, Paucituberculata, Microbiotheria, Dasyuromorphia, Peraamelemorphia, Notoryctemorphia, Diprotodontia, Insectivora, Macroscelidea, Scandentia, Dermoptera, Chiroptera, Primates, Xenarthra, Pholidota, Lagomorpha, Rodentia, Cetacea, Carnivora, Tubulidentata, Proboscidea, Hyracoidea, Sirenia, Perissodactyla and Artiodactyla.

30

Preferably, the mammal is selected from the group consisting of platypus, echidna, kangaroo, wallaby, shrews, moles, hedgehogs, tenrecs, tree shrews, elephant shrews, colugos, bats, primates (including chimpanzees,

gorillas, orangutans, humans), edentates, sloths, armadillos, anteaters, pangolins, rabbits, pikas, rodents, whales, dolphins, porpoises, carnivores, aardvark, elephants, hyraxes, dugongs, manatees, horses, rhinos, 5 tapirs, antelope, giraffe, cows or bulls, bison, buffalo, sheep, big-horn sheep, horses, ponies, donkeys, mule, deer, elk, caribou, goat, water buffalo, camels, llama, alpaca, pigs and hippos.

10 More preferably, the tissue biopsies are isolated from an ungulate selected from the group consisting of domestic or wild bovid, ovid, cervid, suid, equid and camelid.

Especially preferred ungulates are *Bos taurus*, *Bos indicus*, and *Bos* buffalo cows or bulls. 15

The tissue biopsies may be obtained from different organs, eg., skin, lung, pancreas, liver, stomach, intestine, heart, reproductive organs, bladder, kidney, urethra and 20 other urinary organs, etc. Furthermore, the tissue biopsies may be obtained from both fetal and adult tissue.

A fourth aspect provides a method of nuclear transfer comprising the step of transferring a mesenchymal 25 connective tissue-derived stem cell or nuclei isolated from a mesenchymal connective tissue-derived stem cell into an enucleated oocyte.

A fifth aspect provides a method for producing a 30 genetically engineered or transgenic non-human mammal comprising:

(i) inserting, removing or modifying a desired gene in a mesenchymal connective tissue-derived stem cell (MCT) from a non-human mammal or nuclei isolated from a mesenchymal connective tissue-derived stem cell isolated from a non-human mammal; and 35

(ii) transferring the MCT or nuclei into an enucleated oocyte.

5 The invention further provides a method for producing a genetically engineered or transgenic non-human mammal comprising:

10 (i) inserting, removing or modifying a desired gene or genes in a mesenchymal connective tissue-derived stem cell (MCT) from a non-human mammal or nuclei isolated from a mesenchymal connective tissue-derived stem cell isolated from a non-human mammal; and

15 (ii) inserting MCT or nuclei into an enucleated oocyte under conditions suitable for the formation of a reconstituted cell;

20 (iii) activating the reconstituted cell to form an embryo;

(iv) culturing said embryo until greater than the 2-cell developmental stage; and

25 (v) transferring said cultured embryo to a host mammal such that the embryo develops into a transgenic fetus.

A sixth aspect provides a method for cloning a non-human mammal comprising:

30 (i) inserting a mesenchymal connective tissue-derived stem cell (MCT) from a non-human mammal or nuclei isolated from a mesenchymal connective tissue-derived stem cell isolated from a non-human mammal into an enucleated mammalian oocyte, under conditions suitable for the formation of a reconstituted cell;

35 (ii) activating the reconstituted cell to form an embryo;

(iii) culturing said embryo until greater than the 2-cell developmental stage; and

(iv) transferring said cultured embryo to a host mammal such that the embryo develops into a fetus.

5 Oocytes may be isolated from any mammal by known procedures. For example, oocytes can be isolated from either oviducts and/or ovaries of live animals by oviductal recovery procedures or transvaginal oocyte recovery procedures well known in the art and described  
10 herein. Furthermore, oocytes can be isolated from deceased animals. For example, ovaries can be obtained from abattoirs and the oocytes aspirated from these ovaries. The oocytes can also be isolated from the ovaries of a recently sacrificed animal or when the ovary has been  
15 frozen and/or thawed. Preferably, the oocytes are freshly isolated from the oviducts.

Oocytes or cytoplasts may also be cryopreserved before use.

20 In one embodiment, the enucleated oocyte is a zona pellucida-free oocyte. Removal of the zona pellucida can be accomplished by any known procedure. Preferably, the step of removing the zona pellucida is selected from the  
25 group consisting of physical manipulation, chemical treatment and enzymatic digestion. More preferably, the zona pellucida is removed by enzymatic digestion. Preferably, the enzyme used to digest the zona pellucida is a protease, a pronase or a combination thereof. More  
30 preferably, the enzyme is a pronase.

35 Preferably, the pronase is used at a concentration between 0.1 to 5%. More preferably, the concentration is between 0.25% to 2%. Most preferably, the pronase is at a concentration of about 0.5%.

It will be appreciated by those skilled in the art that any procedure of enucleation of the oocyte can be performed, including, aspiration, physical removal, use of DNA-specific fluorochromes, and irradiation with 5 ultraviolet light. Preferably, the enucleation is by physical means. Most preferable, the physical means is bisection.

Preferably, the step of transferring the MCT or MCT nuclei 10 is by fusion. More preferably, the method of fusion is selected from the group consisting of chemical fusion, electrofusion and biofusion. Preferably, the chemical fusion or biofusion is accomplished by exposing the enucleated oocyte and MCT combination to a fusion agent. 15 Preferably, the fusion agent is any compound or biological organism that can increase the probability that portions of plasma membranes from different cells will fuse when an MCT donor is placed adjacent to the enucleated oocyte recipient. Most preferably, the fusion agents are selected 20 from the group consisting of polyethylene glycol (PEG), trypsin, dimethylsulfoxide (DMSO), lectins, agglutinin, viruses, and Sendai virus.

The electrofusion is preferably induced by application of 25 an electrical pulse across the contact/fusion plane. More preferably, the electrofusion comprises the step of delivering one or more electrical pulses to the enucleated oocyte and MCT combination.

30 Also provided by the present invention are mammals obtained according to the above methods, and offspring of those mammals.

BRIEF DESCRIPTION OF THE FIGURES

35 Figure 1 shows the selective growth stimulation of MCTs (red) by high density/high serum culture. Standard cell

culture techniques leads to a successive loss of the MCT population and result in a conventional fibroblast culture.

5 Figure 2 shows the activation of Oct4-promoter in somatic explants of Oct4-eGFP tg mice. Genital ridge of a male fetus (day 14.5 p.c.) with massive expression of GFP in the primordial germ cells is shown under fluorescent (A) and brightfield optics (B). Bar = 150  $\mu$ m. Outgrowth of  
10 mesenchymal explant, under fluorescent (C) and brightfield (D) optics after 2 days of culture. No GFP positive cells were found. In the upper left the explant is visible. After 8 days in culture several GFP positive cells were detectable within the outgrowth (E, F), bar = 140  $\mu$ m.  
15 Confocal analysis of murine MCTs cultured in high serum, G) fluorescent, H) brightfield and I) merged images, bar = 10  $\mu$ m. The GFP is preferentially located in the cytoplasm, probably because it does not contain a nuclear localisation motif. J) shows RT-PCR detection of native  
20 Oct4 transcripts in MCTs; M, DNA ladder; lane 1, MCTs; lane 2, no-RT control of 1; lane 3, ES cells; lane 4, no-RT control of 3; lane 5, no template control.

25 Figure 3 shows the induction of 3D-growth and AP positive cells in porcine MCTs. A and B show the high serum (30%) induction of 3D-colony growth (passage 3, 5d) in porcine fetal fibroblasts. C shows the control culture of the same cell batch cultured in standard medium (10% FCS, 5d). D shows BrdU incorporation in high serum cultures (5d, 30% FCS). Note that only cells within the 3D-colonies (arrows) incorporated BrdU, the surrounding monolayer is unlabelled, inset: another 3D-colony. E shows BrdU incorporation in proliferating fibroblasts (3d, standard medium with 10% FCS), the majority of the cells is  
30 labelled. F shows BrdU incorporation in confluent fibroblasts (5d, standard medium), the majority of the cells became contact-inhibited and stopped to proliferate.  
35

G-J shows the induction of AP-positive cells, accompanied with 3D-colony growth after 2, 4, 6, 8 days in high serum culture. K shows the higher magnification of AP positive cells aggregated in 3D-colony (4 d). L shows individual 5 AP-positive cells within the fibroblast monolayer. Bars = 20 $\mu$ m.

Figure 4 shows the induction of AP-positive 3D-colonies in fetal and adult fibroblast cultures. A shows porcine 10 fibroblasts from fetal and adult origin of the same batches, respectively, were split and cultured with high serum (30%) or standard (10% FCS) conditions in 6-well plates, after 5 days the cultures were fixed and stained for endogenous AP activity. Note the massive induction of 15 AP-positive 3D-colonies in the fetal culture (red dots). B shows the induction of 3D-colony growth and AP is reversible. After six passages with constant 3D-colony formation and AP expression in high serum (30% FCS) fetal cells were trypsinised, replated and cultured for two 20 passages with standard medium (10% FCS) before AP-staining.

Figure 5 shows the proliferative induction by high serum culture. A shows the growth curves of fetal fibroblasts 25 cultured in standard medium (?) containing 10% FCS and high serum medium (?) containing 30% FCS. Cells were enumerated at each passage under a hemocytometer. B shows the mean cell number per passage ( $\pm$ SD) of fibroblasts from the same batch cultured in DMEM with 10% (?) or 30% (?) 30 FCS after 6 days passage. C shows the cell cycle status in standard and high serum culture. Note that the high serum culture displays a normal ploidy.

Figure 6 shows the anchorage-independent growth of MCTs in 35 suspension culture. High serum induced 3D-colonies were isolated, trypsinized to single cell suspensions and seeded into bacteriological dishes to prevent attachment.

A shows that tiny aggregates formed in HS culture medium without supplementation. B shows that HS medium supplemented with retinoic acid ( $10^{-7}$  M) the initial aggregates reattach and show outgrowing cells on the 5 surface. C shows that HS medium supplemented with dexamethasone ( $10^{-7}$  M) spheroids of  $>300$   $\mu$ m size grow over 10-15 days, inset: lower magnification. D shows that dexamethasone-spheroids stained for 10 endogenous AP, bar = 230  $\mu$ m. E shows that expression of vimentin in fibroblasts cultured in standard medium (passage 5), merged image of antibody (red) and nuclei 15 (blue) staining. Loss of vimentin reactivity in cells derived from dexamethasone-spheroids. After 15 days of suspension culture the spheroids were allowed to reattach to gelatinized coverslips and probed with a monoclonal anti-vimentin antibody.

DETAILED DESCRIPTION OF THE INVENTION

20 Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified cell culture techniques, serum, media or methods and may, of course, vary. It is also to be understood that the terminology used herein is for the 25 purpose of describing particular embodiments of the invention only, and is not intended to be limiting which will be limited only by the appended claims.

30 All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety. However, publications mentioned herein are cited for the purpose of describing and disclosing the protocols, reagents and vectors which are reported in the publications and which might be used 35 in connection with the invention. Nothing herein is to be construed as an admission that the invention is not

entitled to antedate such disclosure by virtue of prior invention.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are described in the literature. See, for example, Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a cell" includes a plurality of such cells, and a reference to "an oocyte" is a reference to one or more oocytes, and so forth. Unless defined otherwise, all technical and

scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any materials and methods similar or equivalent to those described herein 5 can be used to practice or test the present invention, the preferred materials and methods are now described.

The present invention relates to methods of producing primary cell cultures. The term "primary cell culture" 10 denotes a mixed cell population of cells that permits interaction of many different cell types isolated from a tissue. The word "primary" takes its usual meaning in the art of tissue culture. For example, a primary culture of epidermal tissue may allow the interaction between 15 mesenchymal and epithelial cells.

The primary cell culture is produced from tissue biopsy material. The term "tissue" refers to a group or layer of similarly specialised cells, which together perform 20 certain special functions. Accordingly, the term "tissue biopsy" as used herein refers to a specimen obtained by removing a group or layer of similarly specialised cells from animals for use in primary cell culture. The term includes aspiration biopsies; brush biopsies; chorionic 25 villus biopsies; endoscopic biopsies; excision biopsies; needle biopsies (specimens obtained by removal by aspiration through an appropriate needle or trocar that pierces the skin, or the external surface of an organ, and into the underlying tissue to be examined); open biopsies; 30 punch biopsies (trephine); shave biopsies; sponge biopsies; and wedge biopsies.

The tissue biopsy may be taken from any animal, for which the study of tissue-specific progenitor cells or stem 35 cell-like cells is required. Suitable mammalian animals include members of the Orders Primates, Rodentia, Lagomorpha, Cetacea, Carnivora, Perissodactyla and

Artiodactyla. Members of the Orders Perissodactyla and Artiodactyla are particularly preferred because of their similar biology and economic importance.

5 For example, Artiodactyla comprise approximately 150 living species distributed through nine families: pigs (Suidae), peccaries (Tayassuidae), hippopotamuses (Hippopotamidae), camels (Camelidae), chevrotains (Tragulidae), giraffes and okapi (Giraffidae), deer 10 (Cervidae), pronghorn (Antilocapridae), and cattle, sheep, goats and antelope (Bovidae). Many of these animals are used as feed animals in various countries. More importantly, with respect to the present invention, many of the economically important animals such as goats, 15 sheep, cattle and pigs have very similar biology and share high degrees of genomic homology.

The Order Perissodactyla comprises horses and donkeys, which are both economically important and closely related. 20 Indeed, it is well known that horses and donkeys interbreed.

In one embodiment, the tissue biopsies will be obtained from ungulates, and in particular, bovids, ovids, cervids, 25 suids, equids and camelids. Examples of such representatives are cows or bulls, bison, buffalo, sheep, big-horn sheep, horses, ponies, donkeys, mule, deer, elk, caribou, goat, water buffalo, camels, llama, alpaca, and pigs. Especially preferred bovine species are *Bos taurus*, 30 *Bos indicus*, and *Bos buffaloes* cows or bulls.

The general purpose of the primary cell culture is to "isolate," "proliferate" or "selectively expand" tissue-specific progenitor cells or stem cell-like cells present 35 in a tissue biopsy. The terms "isolate," "proliferate" or "selectively expand" as used herein refers to the culturing process by which the tissue-specific progenitor

cells or stem cell-like cells are increased in number relative to the other cells present in the tissue biopsy.

The term "progenitor cell" is used synonymously with "stem cell". Both terms refer to an undifferentiated cell which is capable of proliferation and giving rise to more progenitor cells having the ability to generate a large number of mother cells that can in turn give rise to differentiated, or differentiable daughter cells. In a preferred embodiment, the term progenitor or stem cell refers to mesenchymal connective tissue derived stem cell-like cells (MCTs). The characteristics of MCTs are reminiscent of pluripotent stem cells. The MCTs are characterised by loss of contact inhibition, anchorage independent growth, *de novo* expression of alkaline phosphatase and activation of the germ line specific Oct4 promoter. The proliferative potential of these cells is significantly increased compared to primary fibroblasts.

In one embodiment the MCT is the MCT deposited at the ATCC under accession number #12345.

After the tissue biopsy has been obtained, the initial step in the isolation, proliferation or selective expansion of the tissue-specific progenitor cells, stem cell-like cell or MCT present in a tissue biopsy involves the culturing of the tissue biopsy. The terms "culture," "cultured" and "culturing" are used herein interchangeably, to refer to the process by which the tissue biopsy is grown *in vitro*.

The tissue biopsy is preferably subjected to physical and/or chemical dissociating means capable of dissociating cellular stratum in the tissue sample. Methods for dissociating cellular layers within the tissues are well known in the field. For example, the dissociating means may be either a physical or a chemical disruption means.

Physical dissociation means might include, for example, scraping the tissue biopsy with a scalpel, mincing the tissue, physically cutting the layers apart, or perfusing the tissue with enzymes. Chemical dissociation means might

5 include, for example, digestion with enzymes such as trypsin, dispase, collagenase, trypsin-EDTA, thermolysin, pronase, hyaluronidase, elastase, papain and pancreatin. Non-enzymatic solutions for the dissociation of tissue can also be used.

10 In one embodiment, dissociation of the tissue biopsy is achieved by placing the tissue biopsy in a pre-warmed enzyme solution containing an amount of trypsin sufficient to dissociate the cellular stratum in the tissue biopsy.

15 Preferably, the enzyme solution used in the method is calcium and magnesium free.

Where the tissue biopsy is derived from an animal's skin (comprising epithelial and dermal cells) the amount of

20 trypsin that might be used in the method is preferably between about 5 and 0.1% trypsin per volume of solution. Desirable the trypsin concentration of the solution is about 2.5 to 0.25%, with about 0.5% trypsin being most preferred.

25 The time period over which the tissue biopsy is subjected to the trypsin solution may vary depending on the size of the tissue biopsy taken. Preferably the tissue biopsy is placed in the presence of the trypsin solution for

30 sufficient time to weaken the cohesive bonding between the tissue stratum. For example, where the tissue sample is taken from an animal's skin the tissue biopsy might be placed in trypsin for between 5 to 60 minutes. In one embodiment, the tissue biopsy is immersed in the trypsin

35 solution for between 10 and 30 minutes with 15 to 20 minutes being optimal for most tissue biopsies.

After the tissue biopsy has been immersed in the trypsin solution for an appropriate amount of time, the dissociated cells are removed and suspended in tissue culture medium. The terms "culture media," "tissue

5 culture media" or "tissue culture medium" are recognised in the art, and refers generally to any substance or preparation used for the cultivation of living cells. There are a large number of tissue culture media that exist for culturing tissue from animals. Some of these are

10 complex and some are simple. Examples of media that would be useful in the present invention include Modified Eagle's Medium (MEM), Dulbecco's Modified Eagle's Medium (DMEM), RPMI 1640, F-12, IMDM, Alpha Medium and McCoy's Medium. Most preferably, the culture medium is DMEM.

15 In one embodiment, enzymatically dissociated and eviscerated fetuses or mesenchymal explant (<1mm<sup>3</sup>) cultures of connective tissue are suspended in DMEM supplemented with 1mM glutamine, 1% non-essential amino acids, 1%

20 vitamin solution, 0.1 mM mercaptoethanol, 100U/ml penicillin, and 100 mg/ml streptomycin (all from Sigma, Deisenhofen, Germany).

In order to encourage the tissue-specific progenitor cells

25 or stem cell-like cells to proliferate, serum is added to the tissue culture medium. The serum in the culture medium may be allogeneic serum (ie., from the same animal species, but not the same animal), autologous serum (ie., from the same animal) or xenogeneic serum (ie., from a

30 different animal species). In one embodiment, heat-inactivated autologous serum is used.

When the dissociated tissue biopsy is initially cultured the amount of serum used is typically about 10%. The term

35 "about" as used herein to describe the amount of serum used in the culture medium indicates that in certain circumstances the amount of serum used will be slightly

more (approximately 10% more) or slightly less (approximately 10% less), than the stated amount. For example, about 10% serum would mean that as little as 9% serum might be used or up to a maximum of 11% serum.

5 About 30% serum would mean that as little as 27% serum might be used serum (ie within 10% of the stated volume) or as much as 33% serum (ie within 10% of the stated volume).

10 The dissociated tissue biopsy cells, including the tissue-specific progenitor cells or stem cell-like cells are incubated in a humidified 95% air/5% CO<sub>2</sub> atmosphere at 37°C.

15 After the second passage of the cells after setting up the culture, the serum concentration is adjusted to about 30%. The precise timing of this stage is difficult to predict as this will vary depending upon the type of tissue used and the age of the material. For example, fetal tissue is

20 typically faster growing than adult tissue. The presence of the increased serum concentration enables the tissue-specific progenitor cells or stem cell-like cells to proliferate, while the other cells present such as keratinocytes, basal cells, Langerhans cells, fibroblasts

25 and melanocytes, have depressed growth. Approximately, every 48 hours or so, 50% of the culture medium is preferably replaced with fresh medium.

30 As the tissue-specific progenitor cells or stem cell-like cells proliferate they generally take on a 3D appearance. Once the 3D-colonies reach approximately 200-300 µm in diameter they are isolated and trypsinised to obtain single cells suspensions. Subsequently, 10<sup>4</sup> cells are seeded into bacteriological culture dishes to prevent

35 attachment. Supplementation of the culture medium (DMEM/30% FCS) with dexamethasone results in aggregations of small multicellular spheroids usually within 24 hours,

which continue to grow up to a diameter of > 400 $\mu$ m after 10-15 days.

The maximal replicative limit can be determined by

5 serially subpassaging the cells as 12.5 x 10<sup>3</sup> cell aliquots seeded per cm<sup>2</sup> in 6-well-dishes, trysinised after 5-7 days, counted and reseeded.

In one embodiment, the tissue-specific progenitor cells or

10 stem cell-like cells are mesenchymal connective tissue derived stem cell-like cells (MCTs). The MCTs show several characteristics not found in fibroblasts, eg. they have a significantly extended proliferative capacity of >100 cell doublings *in vitro*. This allows an extended amplification

15 of clonal cell strains or mass cultures and could simplify genetic modifications and potentially enables two rounds of genetic modifications and selection. Also enough cells for grafting procedures can be obtained, as MCTs might be suitable for directed differentiation into several cell

20 types. Figure 1 shows the selective growth stimulation of MCTs (red) by high density/high serum culture. Standard cell culture techniques leads to a successive loss of the MCT population and result in a conventional fibroblast culture. One specific type of MCT has been deposited at

25 the ATCC on December 2003 under accession number #12345.

Once the tissue-specific progenitor cells, stem cell-like cells or MCTs have been isolated or proliferated they can

30 then be used, for example, for direct transplantation or to produce differentiated cells *in vitro* for transplantation or in nuclear transfer techniques. The invention accordingly provides, for example, stem cells that may serve as a source for many other, more

35 differentiated cell types.

One embodiment pertains to the progeny of the tissue-

specific progenitor cells, stem cell-like cells or MCTs, eg. those cells which have been derived from the cells of the initial tissue biopsy. Such progeny can include subsequent generations of tissue-specific progenitor

5 cells, stem cell-like cells or MCTs, as well as lineage committed cells generated by inducing differentiation of the tissue-specific progenitor cells, stem cell-like cells or MCTs after their isolation from the tissue biopsy, eg., induced *in vitro*.

10 Another embodiment relates to cellular compositions enriched for tissue-specific progenitor cells, stem cell-like cells or MCTs, or the progeny thereof. In certain embodiments, the cells will be provided as part of a pharmaceutical preparation, eg., a sterile, free of the presence of unwanted virus, bacteria and other pathogens, as well as pyrogen-free preparation. That is, for animal administration, the tissue-specific progenitor cells, stem cell-like cells or MCTs should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

15 In certain embodiments, such cellular compositions can be used for transplantation into animals, preferably mammals, and even more preferably humans. The tissue-specific progenitor cells, stem cell-like cells or MCTs can be autologous, allogeneic or xenogeneic with respect to the transplantation host.

20 Yet another aspect of the present invention concerns cellular compositions, which include as a cellular component, substantially pure preparations of the tissue-specific progenitor cells, stem cell-like cells or MCTs, or the progeny thereof. Cellular compositions of the present invention include not only substantially pure populations of the tissue-specific progenitor cells, stem cell-like cells or MCTs, but can also include cell culture

25

30

35

components, eg., culture media including amino acids, metals, coenzyme factors, as well as small populations of non-tissue-specific progenitor cells, stem cell-like cells or MCTs cells, eg., some of which may arise by subsequent differentiation of isolated tissue-specific progenitor cells, stem cell-like cells or MCTs of the invention. Furthermore, other non-cellular components include those which render the cellular component suitable for support under particular circumstances, eg., implantation, eg., continuous culture.

As common methods of administering the tissue-specific progenitor cells, stem cell-like cells or MCTs of the present invention to animals, particularly humans, which are described in detail herein, include injection or implantation of the tissue-specific progenitor cells, stem cell-like cells or MCTs into target sites in the animals, the cells of the invention can be inserted into a delivery device which facilitates introduction by, injection or implantation, of the cells into the animals. Such delivery devices include tubes, eg., catheters, for injecting cells and fluids into the body of a recipient animal. In a preferred embodiment, the tubes additionally have a needle, eg., a syringe, through which the cells of the invention can be introduced into the animal at a desired location. The tissue-specific progenitor cells, stem cell-like cells or MCTs of the invention can be inserted into such a delivery device, eg., a syringe, in different forms. For example, the cells can be suspended in a solution or embedded in a support matrix when contained in such a delivery device. As used herein, the term "solution" includes a pharmaceutically acceptable carrier or diluent in which the cells of the invention remain viable. Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and/or dispersion media. The use of such carriers and diluents is well known in the art. The solution is preferably sterile

and fluid to the extent that easy syringability exists. Preferably, the solution is stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi through the use of, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. Solutions of the invention can be prepared by incorporating tissue-specific progenitor cells, stem cell-like cells or MCTs as described herein in a pharmaceutically acceptable carrier or diluent and, as required, other ingredients enumerated above, followed by filtered sterilisation.

Support matrices in which the tissue-specific progenitor cells, stem cell-like cells or MCTs can be incorporated or embedded include matrices which are recipient-compatible and which degrade into products which are not harmful to the recipient. Natural and/or synthetic biodegradable matrices are examples of such matrices. Natural biodegradable matrices include plasma clots, eg., derived from a mammal, and collagen matrices. Synthetic biodegradable matrices include synthetic polymers such as polyanhydrides, polyorthoesters, and polylactic acid. Other examples of synthetic polymers and methods of incorporating or embedding cells into these matrices are known in the art. See eg., U.S. Pat. Nos. 4,298,002 and 5,308,701. These matrices provide support and protection for the fragile progenitor cells *in vivo* and are, therefore, the preferred form in which the tissue-specific progenitor cells, stem cell-like cells or MCTs are introduced into the recipient animals.

The present invention also provides substantially pure tissue-specific progenitor cells, stem cell-like cells or MCTs cells which can be used therapeutically for treatment of various disorders.

To illustrate, the tissue-specific progenitor cells, stem cell-like cells or MCTs of the invention can be used in the treatment or prophylaxis of a variety of disorders. For instance, the tissue-specific progenitor cells, stem 5 cell-like cells or MCTs can be used to produce populations of differentiated cells for repair of damaged tissue eg pancreatic tissue, cardiac tissue, nerves and the like. Likewise, such cell populations can be used to regenerate or replace pancreatic tissue, cardiac tissue or nerves 10 lost due to, pancreatolysis, eg., destruction of pancreatic tissue, such as pancreatitis, heart disease or neuropathy.

Yet another embodiment provides methods for screening 15 various compounds for their ability to modulate growth, proliferation or differentiation of tissue-specific progenitor cells, stem cell-like cells or MCTs. In an illustrative embodiment, the subject tissue-specific progenitor cells, stem cell-like cells or MCTs, and their 20 progeny, can be used to screen various compounds or natural products. Such explants can be maintained in minimal culture media for extended periods of time (eg., for 7-21 days or longer) and can be contacted with any compound, eg., small molecule or natural product, eg., 25 growth factor, to determine the effect of such compound on one of cellular growth, proliferation or differentiation of the tissue-specific progenitor cells, stem cell-like cells or MCTs. Detection and quantification of growth, proliferation or differentiation of these cells in 30 response to a given compound provides a means for determining the compound's efficacy at inducing one of the growth, proliferation or differentiation. Methods of measuring cell proliferation are well known in the art and most commonly include determining DNA synthesis 35 characteristic of cell replication. There are numerous methods in the art for measuring DNA synthesis, any of which may be used according to the invention. In an

embodiment of the invention, DNA synthesis has been determined using a radioactive label (<sup>3</sup>H-thymidine) or labelled nucleotide analogues (BrdU) for detection by immunofluorescence. The efficacy of the compound can be 5 assessed by generating dose response curves from data obtained using various concentrations of the compound. A control assay can also be performed to provide a baseline for comparison. Identification of the progenitor cell 10 population(s) amplified in response to a given test agent can be carried out according to such phenotyping as described above.

In one embodiment, the tissue-specific progenitor cells, stem cell-like cells or MCTs are used for cloning mammals 15 by nuclear transfer or nuclear transplantation. In the subject application, the terms "nuclear transfer" or "nuclear transplantation" are used interchangeably; however, these terms as used herein refers to introducing a full complement of nuclear DNA from one cell to an 20 enucleated cell.

The first step in the preferred methods involves the isolation of a recipient oocyte from a suitable animal. In this regard, the oocyte may be obtained from any animal 25 source and at any stage of maturation. Methods for isolation of oocytes are well known in the art. For example, oocytes can be isolated from either oviducts and/or ovaries of live animals by oviductal recovery procedures or transvaginal oocyte recovery procedures well 30 known in the art. See, e.g., Pieterse et al., 1988, "Aspiration of bovine oocytes during transvaginal ultrasound scanning of the ovaries," Theriogenology 30: 751-762. Furthermore, oocytes can be isolated from ovaries or oviducts of deceased animals. For example, 35 ovaries can be obtained from abattoirs and the oocytes aspirated from these ovaries. The oocytes can also be isolated from the ovaries of a recently sacrificed animal

or when the ovary has been frozen and/or thawed.

Briefly, in one preferred embodiment, immature (prophase I) oocytes from mammalian ovaries are harvested by aspiration. For the successful use of techniques such as genetic engineering, nuclear transfer and cloning, once these oocytes have been harvested they must generally be matured *in vitro* before these cells may be used as recipient cells for nuclear transfer.

10 The stage of maturation of the oocyte at enucleation and nuclear transfer has been reported to be significant to the success of nuclear transfer methods. (See eg., Prather et al., *Differentiation*, 48, 1-8, 1991). In general, successful mammalian embryo cloning practices use the metaphase II stage oocyte as the recipient oocyte because at this stage it is believed that the oocyte can be or is sufficiently activated to treat the introduced nucleus as it does a fertilising sperm.

15 20 The *in vitro* maturation of oocytes usually takes place in a maturation medium until the oocyte has extruded the first polar body, or until the oocyte has attained the metaphase II stage. In domestic animals, and especially cattle, the oocyte maturation period generally ranges from about 16-52 hours, preferably about 28-42 hours and more preferably about 18-24 hours post-aspiration. For purposes of the present invention, this period of time is known as the "maturation period."

25 30 Oocytes can be matured in a variety ways and using a variety of media well known to a person of ordinary skill in the art. See, eg., U.S. Patent No. 5,057,420; Saito et al., 1992, *Roux's Arch. Dev. Biol.* 201: 134-141 for bovine organisms and Wells et al., 1997, *Biol. Repr.* 57: 385-393 for ovine organisms and WO97/07668, entitled "Unactivated Oocytes as Cytoplasm Recipients for Nuclear Transfer," all

hereby incorporated herein by reference in the entirety, including all figures, tables, and drawings.

One of the most common media used for the collection and 5 maturation of oocytes is TCM-199, and 1 to 20% serum supplement including fetal calf serum (FCS), newborn serum, estrual cow serum, lamb serum or steer serum. Example 1 shows one example of a preferred maintenance medium: TCM-199 with Earl salts supplemented with 15% cow 10 serum and including 10IU/ml pregnant mare serum gonadotropin and 5IU/ml human chorionic gonadotropin (Suigonan<sup>R</sup> Vet, Intervet, Australia). Oocytes can be successfully matured in this type of medium within an environment comprising 5% CO<sub>2</sub> at 39°C.

15 While it will be appreciated by those skilled in the art that freshly isolated and matured oocytes are preferred, it will also be appreciated that it is possible to cryopreserve the oocytes after harvesting or after 20 maturation. Accordingly, the term "cryopreserving" as used herein can refer to freezing an oocyte, a cell, embryo, or animal of the invention. The oocytes, cells, embryos, or portions of animals of the invention are frozen at temperatures preferably lower than 0°C, more 25 preferably lower than -80°C, and most preferably at temperatures lower than -196°C. Oocytes, cells and embryos in the invention can be cryopreserved for an indefinite amount of time. It is known that biological materials can be cryopreserved for more than fifty years. For example, 30 semen that is cryopreserved for more than fifty years can be utilised to artificially inseminate a female bovine animal. Methods and tools for cryopreservation are well known to those skilled in the art. See, eg., U.S. Patent No. 5,160,312, entitled "Cryopreservation Process for 35 Direct Transfer of Embryos".

If cyropreserved oocytes are utilised then these must be

initially thawed before placing the oocytes in maturation medium. Methods of thawing cryopreserved materials such that they are active after the thawing process are well-known to those of ordinary skill in the art.

5

In a further preferred embodiment, mature (metaphase II) oocytes, which have been matured *in vivo*, are harvested and used in the nuclear transfer methods disclosed herein. Essentially, mature metaphase II oocytes are collected

10 surgically from either non-superovulated or superovulated cows or heifers 35 to 48 hours past the onset of estrus or past the injection of human chorionic gonadotropin (hCG) or similar hormone.

15 Where oocytes have been cultured *in vitro* cumulus cells that may have accumulated may be removed to provide oocytes that are at a more suitable stage of maturation for enucleation. Cumulus cells may be removed by pipetting or vortexing, for example, in the presence of

20 0.5% hyaluronidase.

After the maturation period as described above the zona pellucida may be removed from the oocytes if desired. The advantages of zona pellucida removal are described in

25 PCT/AU02/00491, which is incorporated in its entirety herein by reference. The removal of the zona pellucida from the oocyte may be carried out by any method known in the art including physical manipulation (mechanical opening), chemical treatment or enzymatic digestion (Wells and Powell, 2000). Physical manipulation may involve the use of a micropipette or a microsurgical blade. Preferably, enzymatic digestion is used.

30 In one particularly preferred embodiment, the zona pellucida is removed by enzymatic digestion in the presence of a protease or pronase. Briefly, mature oocytes are placed into a solution comprising a protease,

pronase or combination of each at a total concentration in the range of 0.1% - 5%, more preferably 0.25% - 2% and most preferably about 0.5%. The mature oocyte is then allowed to incubate at between 30°C to about 45°C,

5 preferably about 39°C for a period of 1 to 30 minutes. Preferably the oocytes are exposed to the enzyme for about 5 minutes. Although pronase may be harmful to the membranes of oocytes, this effect may be minimised by addition of serum such as FCS or cow serum. The unique

10 advantage of zona removal with pronase is that no individual treatment is required, and the procedure can be performed in quantities of 100's of oocytes. Once the zona pellucida has been removed the zona pellucida-free mature oocyte are rinsed in 4ml Hepes buffered TCM-199

15 medium supplemented with 20% FCS and 10µg/ml cytochalasin B and then enucleated.

20 The terms "enucleation", "enucleated" and "enucleated oocyte" are used interchangeably herein and refers to an oocyte which has had part of its contents removed.

Enucleation of the oocyte may be achieved physically, by actual removal of the nucleus, pronuclei or metaphase plate (depending on the oocyte), or functionally, such as

25 by the application of ultraviolet radiation or another enucleating influence. All of these methods are well known to those of ordinary skill in the art. For example, physical means includes aspiration (Smith & Wilmut, Biol. Reprod., 40: 1027-1035 (1989)); functional means include

30 use of DNA-specific fluorochromes (See, for example, Tsunoda et al., J. Reprod. Fertil. 82: 173 (1988)), and irradiation with ultraviolet light (See, for example, Gurdon, Q. J. Microsc. Soc., 101: 299-311 (1960)).

Enucleation may also be effected by other methods known in

35 the art. See, for example, U.S. Patent 4,994,384; U.S. Patent 5,057,420; and Willadsen, 1986, Nature 320:63-65, herein incorporated by reference.

Preferably, the oocyte is enucleated by means of manual bisection. Oocyte bisection may be carried out by any method known to those skilled in the art. In one 5 preferred embodiment, the bisection is carried out using a microsurgical blade as described in International Patent Application No. WO98/29532 which is incorporated by reference herein. Briefly, oocytes are split asymmetrically into fragments representing approximately 10 30% and 70% of the total oocyte volume using an ultra sharp splitting blade (AB Technology, Pullman, WA, USA). The oocytes may then be screened to identify those of 15 which have been successfully enucleated. This screening may be effected by staining the oocytes with 1 microgram per millilitre of the Hoechst fluorochrome 33342 dissolved in TCM-199 media supplemented with 20% FCS, and then viewing the oocytes under ultraviolet irradiation with an inverted microscope for less than 10 seconds. The oocytes 20 that have been successfully enucleated (demi-oocytes) can then be placed in a suitable culture medium, eg., TCM-199 media supplemented with 20% FCS.

In the present invention, the recipient oocytes will 25 preferably be enucleated at a time ranging from about 10 hours to about 40 hours after the initiation of *in vitro* maturation, more preferably from about 16 hours to about 24 hours after initiation of *in vitro* maturation, and most preferably about 16-18 hours after initiation of *in vitro* maturation.

30 The bisection technique described herein requires much less time and skill than other methods of enucleation and the subsequent selection by staining results in high accuracy. Consequently, for large-scale application of 35 cloning technology the present bisection technique can be more efficient than other techniques.

A single tissue-specific progenitor cell, stem cell-like cell or MCTs of the present invention of the same species as the enucleated oocyte can then be transferred by fusion into the enucleated oocyte thereby producing a  
5 reconstituted cell.

Analysis of cell cycle stage may be performed as described in Kubota et al., PNAS 97: 990-995 (2000). Briefly, cell cultures at different passages are grown to confluence.  
10 After trypsinisation, cells are washed with TCM-199 plus 10% FCS and re-suspended to a concentration of  $5 \times 10^5$  cells/ml in 1ml PBS with glucose (6.1 mM) at 4°C. Cells are fixed overnight by adding 3ml of ice-cold ethanol. For nuclear staining, cells are then pelleted, washed with PBS  
15 and re-suspended in PBS containing 30 $\mu$ g/ml propidium iodide and 0.3mg/ml RNase A. Cells are allowed to incubate for 1h at room temperature in the dark before filtered through a 30 $\mu$ m mesh. Cells are then analyzed.  
20 To examine the ploidy of the tissue-specific progenitor cells, stem cell-like cells or MCTs at various passages, chromosome counts may be determined at different passages of culture using standard preparation of metaphase spreads (See, for example, Kubota et al., PNAS 97: 990-995  
25 (2000)).

Cultured tissue-specific progenitor cells, stem cell-like cells or MCTs may also be genetically altered by transgenic methods well-known to those of ordinary skill in the art. See, for example, Molecular Cloning a Laboratory Manual, 2nd Ed., 1989, Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory Press; U.S. Pat. No. 5,612,205; U.S. Pat. No. 5,633,067; EPO 264 166, entitled "Transgenic Animals Secreting Desired Proteins Into Milk"; WO94/19935, entitled "Isolation of Components of Interest From Milk"; WO93/22432, entitled "Method for Identifying Transgenic Pre-implantation Embryos"; and

WO95/175085, entitled "Transgenic Production of Antibodies in Milk," all of which are incorporated by reference herein in their entirety including all figures, drawings and tables. Any known method for inserting, deleting or

5 modifying a desired gene from a mammalian cell may be used for altering the tissue-specific progenitor cells, stem cell-like cells or MCTs to be used as the nuclear donor. These procedures may remove all or part of a gene, and the gene may be heterologous. Included is the technique of

10 homologous recombination, which allows the insertion, deletion or modification of a gene or genes at a specific site or sites in the cell genome.

Examples for modifying a target DNA genome by deletion, insertion, and/or mutation are retroviral insertion, artificial chromosome techniques, gene insertion, random insertion with tissue specific promoters, gene targeting, transposable elements and/or any other method for introducing foreign DNA or producing modified DNA/modified

15 nuclear DNA. Other modification techniques include deleting DNA sequences from a genome and/or altering nuclear DNA sequences. Nuclear DNA sequences, for example, may be altered by site-directed mutagenesis.

20

25 The present invention can thus be used to provide adult mammals with desired genotypes. Multiplication of adult ungulates with proven genetic superiority or other desirable traits is particularly useful, including transgenic or genetically engineered animals, and chimeric

30 animals. Furthermore, cell and tissues from the nuclear transfer fetus, including transgenic and/or chimeric fetuses, can be used in cell, tissue and organ transplantation.

35 Methods for generating transgenic cells typically include the steps of (1) assembling a suitable DNA construct useful for inserting a specific DNA sequence into the

nuclear genome of tissue-specific progenitor cells, stem cell-like cells or MCTs; (2) transfecting the DNA construct into the tissue-specific progenitor cells, stem cell-like cells or MCTs; (3) allowing random insertion 5 and/or homologous recombination to occur. The modification resulting from this process may be the insertion of a suitable DNA construct(s) into the target genome; deletion of DNA from the target genome; and/or mutation of the target genome.

10 DNA constructs can comprise a gene of interest as well as a variety of elements including regulatory promoters, insulators, enhancers, and repressors as well as elements for ribosomal binding to the RNA transcribed from the DNA 15 construct.

DNA constructs can also encode ribozymes and anti-sense DNA and/or PNA, identified previously herein. These examples are well known to a person of ordinary skill in 20 the art and are not meant to be limiting.

Due to the effective recombinant DNA techniques available in conjunction with DNA sequences for regulatory elements and genes readily available in data bases and the 25 commercial sector, a person of ordinary skill in the art can readily generate a DNA construct appropriate for establishing transgenic cells using the materials and methods described herein.

30 Transfection techniques are well known to a person of ordinary skill in the art and materials and methods for carrying out transfection of DNA constructs into cells are commercially available. Materials typically used to transfect cells with DNA constructs are lipophilic 35 compounds, such as Lipofectin™ for example. Particular lipophilic compounds can be induced to form liposomes for mediating transfection of the DNA construct into the

cells.

Target sequences from the DNA construct can be inserted into specific regions of the nuclear genome by rational 5 design of the DNA construct. These design techniques and methods are well known to a person of ordinary skill in the art. See, for example, U.S. Patent 5,633,067; U.S. Patent 5,612,205 and PCT publication WO93/22432, all of which are incorporated by reference herein in their 10 entirety. Once the desired DNA sequence is inserted into the nuclear genome, the location of the insertion region as well as the frequency with which the desired DNA sequence has inserted into the nuclear genome can be identified by methods well known to those skilled in the 15 art.

Once the transgene is inserted into the nuclear genome of the donor tissue-specific progenitor cells, stem cell-like cells or MCTs, that cell, like other donor tissue-specific 20 progenitor cells, stem cell-like cells or MCTs of the invention, can be used as a nuclear donor in nuclear transfer methods. The means of transferring the nucleus of a tissue-specific progenitor cells, stem cell-like cells or MCTs into the enucleated oocyte preferably 25 involves cell fusion to form a reconstituted cell.

Fusion is typically induced by application of a DC electrical pulse across the contact/fusion plane, but additional AC current may be used to assist alignment of 30 donor and recipient cells. Electrofusion produces a pulse of electricity that is sufficient to cause a transient breakdown of the plasma membrane and which is short enough that the membrane reforms rapidly. Thus, if two adjacent membranes are induced to breakdown and upon reformation 35 the lipid bilayers intermingle, small channels will open between the two cells. Due to the thermodynamic instability of such a small opening, it enlarges until the

two cells become one. Reference is made to U.S. Pat. No. 4,997,384 by Prather et al., (incorporated by reference in its entirety herein) for a further discussion of this process. A variety of electrofusion media can be used 5 including eg., sucrose, mannitol, sorbitol and phosphate buffered solution.

Fusion can also be accomplished using Sendai virus as a fusogenic agent (Graham, Wister Inot. Symp. Monogr., 9, 10 19, 1969). Fusion may also be induced by exposure of the cells to fusion-promoting chemicals, such as polyethylene glycol.

Preferably, the donor tissue-specific progenitor cells, 15 stem cell-like cells or MCTs and enucleated oocyte are placed in a 500 $\mu$ m fusion chamber and covered with 4ml of 26°C-27°C fusion medium (0.3M mannitol, 0.1mM MgSO<sub>4</sub>, 0.05mM CaCl<sub>2</sub>). The cells are then electrofused by application of a double direct current (DC) electrical pulse of 70-100V 20 for about 15 $\mu$ s, approximately 1s apart. After fusion, the resultant fused reconstituted cells are then placed in a suitable medium until activation, eg., TCM-199 medium.

In a preferred method of cell fusion the donor tissue-specific progenitor cell, stem cell-like cell or MCT is 25 firstly attached to the enucleated oocyte. For example, a compound is selected to attach the progenitor cell, stem cell-like cell or MCT to the enucleated oocyte to enable fusing of the donor cell and enucleated oocyte membranes. 30 The compound may be any compound capable of agglutinating cells. The compound may be a protein or glycoprotein capable of binding or agglutinating carbohydrate. More preferably the compound is a lectin. The lectin may be selected from the group including Concanavalin A, 35 Canavalin A, Ricin, soybean lectin, lotus seed lectin and phytohemagglutinin (PHA). Preferably the compound is PHA.

In one preferred embodiment, the method of electrofusion described above also comprises a further fusion step, or the fusion step comprises described above comprises one donor progenitor cell, stem cell-like cell or MCT and two 5 or more enucleated oocytes. The double fusion method has the advantageous effect of increasing the cytoplasmic volume of the reconstituted cell.

10 A reconstituted cell is typically activated by electrical and/or non-electrical means before, during, and/or after fusion of the nuclear donor and recipient oocyte (See, for example, Susko-Parrish et al., U.S. Pat. No. 5,496,720). Activation methods include:

- 15 1). Electric pulses;
- 2). Chemically induced shock;
- 3). Penetration by sperm;
- 4). Increasing levels of divalent cations in the oocyte by introducing divalent cations into the oocyte cytoplasm, eg., magnesium, strontium, barium or calcium, 20 eg., in the form of an ionophore. Other methods of increasing divalent cation levels include the use of electric shock, treatment with ethanol and treatment with caged chelators; and
- 25 5). Reducing phosphorylation of cellular proteins in the oocyte by known methods, eg., by the addition of kinase inhibitors, eg., serine-threonine kinase inhibitors, such as 6-dimethyl-aminopurine, staurosporine, 2-aminopurine, and sphingosine. Alternatively, phosphorylation of cellular proteins may be 30 inhibited by introduction of a phosphatase into the oocyte, eg., phosphatase 2A and phosphatase 2B.

35 The activated reconstituted cells, or embryos, are typically cultured in medium well known to those of ordinary skill in the art, and include, without limitation, TCM-199 plus 10% FSC, Tyrodes-Albumin-Lactate-Pyruvate (TALP), Ham's F-10 plus 10% FCS, synthetic

oviductal fluid ("SOF"), B2, CRLaa, medium and high potassium simplex medium ("KSOM").

The reconstituted cell may also be activated by known methods. Such methods include, eg., culturing the reconstituted cell at sub-physiological temperature, in essence by applying a cold, or actually cool temperature shock to the reconstituted cell. This may be most conveniently done by culturing the reconstituted cell at room temperature, which is cold relative to the physiological temperature conditions to which embryos are normally exposed. Suitable oocyte activation methods are the subject of U.S. Pat. No. 5,496,720, to Susko-Parrish et al., herein incorporated by reference in its entirety.

The activated reconstituted cells may then be cultured in a suitable *in vitro* culture medium until the generation of cells and cell colonies. Culture media suitable for culturing and maturation of embryos are well known in the art. Examples of known media, which may be used for bovine embryo culture and maintenance, include Ham's F-10 plus 10% FCS, TCM-199 plus 10% FCS, Tyrodes-Albumin-Lactate-Pyruvate (TALP), Dulbecco's Phosphate Buffered Saline (PBS), Eagle's and Whitten's media. One of the most common media used for the collection and maturation of oocytes is TCM-199, and 1 to 20% serum supplement including fetal calf serum, newborn serum, estrual cow serum, lamb serum or steer serum. A preferred maintenance medium includes TCM-199 with Earl salts, 10% FSC, 0.2mM Na pyruvate and 50 $\mu$ g/ml gentamicin sulphate. Any of the above may also involve co-culture with a variety of cell types such as granulosa cells, oviduct cells, BRL cells and uterine cells and STO cells.

Afterward, the cultured reconstituted cell or embryos are preferably washed and then placed in a suitable media, eg., TCM-199 medium containing 10% FCS contained in well

plates which preferably contain a suitable confluent feeder layer. Suitable feeder layers include, by way of example, fibroblasts and epithelial cells, e.g., fibroblasts and uterine epithelial cells derived from 5 ungulates, chicken fibroblasts, murine (e.g., mouse or rat) fibroblasts, STO and SI-m220 feeder cell lines, and BRL cells.

10 In one embodiment, the feeder cells comprise mouse embryonic fibroblasts. Preparation of a suitable fibroblast feeder layers are well known in the art.

15 The reconstituted cells are cultured on the feeder layer until the reconstituted cells reach a size suitable for transferring to a recipient female, or for obtaining cells which may be used to produce cells or cell colonies. Preferably, these reconstituted cells will be cultured until at least about 2 to 400 cells, more preferably about 4 to 128 cells, and most preferably at least about 50 20 cells. The culturing will be effected under suitable conditions, i.e., about 39°C. and 5% CO<sub>2</sub>, with the culture medium changed in order to optimise growth typically about every 2-5 days, preferably about every 3 days.

25 The methods for embryo transfer and recipient animal management in the present invention are standard procedures used in the embryo transfer industry. Synchronous transfers are important for success of the present invention, i.e., the stage of the nuclear transfer 30 embryo is in synchrony with the estrus cycle of the recipient female. This advantage and how to maintain recipients are reviewed in Siedel, G. E., Jr. ("Critical review of embryo transfer procedures with cattle" in Fertilization and Embryonic Development in Vitro (1981) L. 35 Mastroianni, Jr. and J. D. Biggers, ed., Plenum Press, New York, N.Y., page 323), the contents of which are hereby incorporated by reference.

Briefly, blastocysts may be transferred non-surgically or surgically into the uterus of a synchronized recipient. Other medium may also be employed using techniques and

5 media well-known to those of ordinary skill in the art. In one procedure, cloned embryos are washed three times with fresh KSOM and cultured in KSOM with 0.1% BSA for 4 days and subsequently with 1% BSA for an additional 3 days, under 5% CO<sub>2</sub>, 5% O<sub>2</sub> and 90% N<sub>2</sub> at 39°C. Embryo development

10 is examined and graded by standard procedures known in the art. Cleavage rates are recorded on day 2 and cleaved embryos are cultured further for 7 days. On day seven, blastocyst development is recorded and one or two embryos, pending availability of embryos and/or animals, is

15 transferred non-surgically into the uterus of each synchronized foster mother.

Foster mothers preferably are examined for pregnancy by rectal palpation or ultrasonography periodically, such as

20 on days 40, 60, 90 and 120 of gestation. Careful observations and continuous ultrasound monitoring (monthly) preferably is made throughout pregnancy to evaluate embryonic loss at various stages of gestation. Any aborted fetuses should be harvested, if possible, for

25 DNA typing to confirm clone status as well as routine pathological examinations.

The reconstituted cell, activated reconstituted cell, fetus and animal produced during the steps of such method, and cells, nuclei, and other cellular components which may be harvested therefrom, are also asserted as embodiments of the present invention. It is particularly preferred that the term animal produced be a viable animal.

35 The present invention can also be used to produce embryos, fetuses or offspring which can be used, for example, in cell, tissue and organ transplantation. By taking a fetal

or adult cell from an animal and using it in the cloning procedure a variety of cells, tissues and possibly organs can be obtained from cloned fetuses as they develop through organogenesis. Cells, tissues, and organs can be

5 isolated from cloned offspring as well. This process can provide a source of "materials" for many medical and veterinary therapies including cell and gene therapy. If the cells are transferred back into the animal in which the cells were derived, then immunological rejection is

10 averted. Also, because many cell types can be isolated from these clones, other methodologies such as hematopoietic chimerism can be used to avoid immunological rejection among animals of the same species.

15 Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.

20 The invention will now be further described by way of reference only to the following non-limiting examples. It should be understood, however, that the examples following are illustrative only, and should not be taken in any way

25 as a restriction on the generality of the invention described above. In particular, while the invention is described in detail in relation to the use of mouse and porcine cells, it will be clearly understood that the findings herein are not limited to these types of cells,

30 but would be useful growing any type of cell from any animal.

EXAMPLE 1

ACTIVATION OF THE GERMLINE-SPECIFIC Oct4  
PROMOTER IN MURINE SOMATIC EXPLANT CULTURES

35 OG2-transgenic mice carrying the GFP reporter gene under transcriptional control of the exclusively germline-

specific Oct-4 promoter, were employed for fetal explant cultures. Mesenchymal explants with an average size of  $<1\text{mm}^3$  were isolated from fetuses of days 11.5, 13.5 and 14.5 p.c., pasted with microdrops of bovine plasma to cell culture dishes and cultured individually in DMEM/10% FCS. Specific care was taken to isolate explants from connective tissue of the neck and shoulder regions. Fluorescence microscopy revealed no GFP positive-cells in the initial explants and GFP expression could not be detected in the first outgrowths after 2 days (Figure 2C, D). However, after 8 days of culture, GFP positive cells, indicative for the activation of the germ line-specific Oct4-eGFP marker cassette, were clearly detectable within the primary outgrowing cells (Figure 2E, F). Subpassages of the outgrowing cells cultured in DMEM supplemented with 30% FCS maintained GFP-positive cells (Figure 2G-I), however at relative low frequencies of  $10^{-2}$ - $10^{-3}$ . The expression of the endogenous Oct4 gene was confirmed by RT-PCR detection of the corresponding mRNA in subpassages of the mesenchymal outgrowths (Figure 2J). The genital ridges of the fetuses served as positive controls for the tissue-specificity of the Oct4-GFP cassette; the primordial germ cells showed massive expression of GFP for several days in culture (Figure 2A, B), no outgrowing GFP positive cells could be detected.

EXAMPLE 2      INDUCTION OF AP EXPRESSION AND LOSS OF CONTACT-INHIBITION

30 The isolation of Oct4 expressing cells from murine somatic explants raised the question whether similar cells could be obtained from livestock species. Mesenchymal explants of porcine fetuses (day 25 p.c.) were established and subpassaged once using standard culture protocols yielding 35 morphologically homogenous cell cultures. Immunostaining showed uniform labelling with a vimentin specific and no labelling with a cytokeratin-specific antibody (data not

shown), indicative for fibroblasts. RT-PCR with porcine Oct4 specific primers prove that cultures maintained in DMEM/30% FCS activated the germ line specific Oct4 gene (not shown).

5

Upon change of the culture medium to high serum concentrations, ie. DMEM containing 30% FCS, the cultures did no longer show contact-inhibition. After confluence was reached the growth of 3D-colonies became apparent 10 (Figure 3A, B). Only cells within the 3D-colonies proliferated as measured by BrdU incorporation, whereas the surrounding monolayer-forming cells were mitotically inactive (Figure 3D). Control experiments with standard conditions showed 80% BrdU-labelled cells during the 15 proliferative phase of subconfluent, and < 2% BrdU positive cells in confluent cultures (Figure 3E, F).

Staining for endogenous alkaline phosphatase (AP) activity 20 revealed a massive induction of AP-positive cells, which were nearly exclusively accumulated within the 3D-colonies (Figure 3G-J). AP-positive cells showed a different morphology (Figure 3K, L) from that of the common fibroblast-like type in that they displayed a dendritic morphology. If cells from the same batch were grown under 25 standard culture conditions (with 10% FCS), the cultures became contact-inhibited, 3D-colony growth (Figure 3C) did not occur and AP-positive cells were only rarely found at a frequency of  $10^{-3}$ - $10^{-4}$  (Table 1). Approximately 6.7 % of microwells seeded with ten cells from high serum cultures 30 resulted in continuously growing cultures, suggesting that 1 out of 150 cells was able to initiate clonal growth. The effects of high serum supplementation were heat and trypsin sensitive (data not shown).

Tab.1 High serum induction of AP-positive cells and 3D-colonies in porcine and murine cell isolates

age of donors	tissue source	method	n	high serum induced	
				AP-positive cells (fold increase compared to standard cultures)	3D-colonies (no. / 6-well)
porcine	day 25-27 p.c.	mesoderm	try.	2	250- 850
	day 25 p.c.	mesoderm	expl.	12	100-1000
	0.5-1.5 years	ear biopsy	expl.	3	2-10
murine	day 11.5 p.c.	mesoderm	expl.	3	8
	day 13.5 p.c.	mesoderm	expl.	1	3
	day 14.5 p.c.	mesoderm	expl.	3	11
	4 months	subdermal tissue	expl.	1	1.5

Abbr.: try., trypsinisation of pooled fetuses (n = 6-8), expl., explant cultures from individual fetuses or adult subdermal tissues

5

10

Adult porcine fibroblasts (3 different origins, 0.5-1.5 y old donors) derived from subdermal tissue explants did not display 3D-colony growth (Figure 3) when cultured in

5 DMEM/30%FCS. However, the frequency of AP expressing cells was increased 2-10 fold in high serum cultures compared to control cultures (Table 1) while for fetal cells a 100-1000 fold increase had been calculated. Induction of 3D-colony growth and AP expression in murine cultures was at

10 least one order of magnitude lower than in porcine cultures (Table 1).

Apparently the altered phenotype of porcine fetal cultures was reversible. When high serum cultures were split and

15 one part of the population was returned to standard medium, colony-growth ceased and AP-positive cells disappeared nearly completely within two passages, suggesting that induction and proliferation of MCTs are dependent upon high serum levels in culture (Figure 4B).

20

EXAMPLE 3      INCREASED PROLIFERATIVE POTENTIAL

Culture medium supplemented with high-serum resulted in a dramatically altered growth curve (Figure 5). Cultures

25 maintained under high serum conditions grew continuously over a period of >120 days and exceeded more than 100 cell doublings without reaching a plateau phase (Figure 5A). In contrast, standard cultures, ie. DMEM with 10% FCS, were compatible with only 50-60 cell doublings before mitotic

30 activity ceased after app. 70 days. The total cell number of the DMEM/30% FCS cultures exceeded that of the standard cultures by a factor of up to 2.5 at each subpassage (Figure 5B). The MCTs maintained a diploid status, as measured by fluorescence activated cell sorting (Figure

35 5C) and metaphase spreads.

EXAMPLE 4 FORMATION OF SPHEROIDS AND ANCHORAGE-INDEPENDENT GROWTH

To investigate the growth potential of the colony forming  
5 fetal cells, 3D-colonies of 200-300  $\mu\text{m}$  diameter were isolated and trypsinised to obtain single cells suspensions. Subsequently,  $10^4$  cells were seeded into bacteriological culture dishes to prevent attachment. Supplementation of the culture medium (DMEM/30% FCS) with  
10 dexamethasone resulted in aggregation of small multicellular spheroids within 24 hours, which continued to grow up to a diameter of  $> 400\mu\text{m}$  after 10-15 days and contained nearly exclusively AP positive cells (Figure 6C, D). Initially tiny aggregates were formed in culture  
15 medium supplemented with retinoic acid, which after 2-4 days attached to the surface and showed extensive outgrowth (Figure 6B). In DMEM/30%FCS without supplement, small irregular aggregates consisting of only few cells (2-20) were detected. These cells did not expand and the  
20 majority apparently underwent cell death (Figure 6A). If plated on gelatinised coverslips, dexamethasone-spheroids reattach and monolayer cells grew out. Immunohistology with a monoclonal antibody against vimentin showed no labelling, whereas control cultures kept in standard  
25 medium with 10% FCS were strongly positive (Figure 6 E, F).

DISCUSSION

30 The present demonstrate the presence of tissue-specific progenitor cells or stem cell-like cells (MCTs) in fetal mesenchymal tissue cultures of rodents and livestock species that can be specifically enriched by the methods disclosed herein. MCT cells are characterised by extended  
35 proliferative capacity, altered morphology, *de novo* expression of the stem cell markers Oct4 and AP, as well as contact- and anchorage-independent growth.

The explant culture technique employing higher than normal serum levels seems to be essential for an initially stimulation of the MCT proliferation. Standard culture 5 using low serum levels of 10% or less are associated with a progressive loss of MCTs.

Transcriptional activity of the Oct4 promoter in MCTs indicates that these cells have characteristics of stem 10 cells. Oct4 controls the expression of several genes including Fgf4, Rex-1, Sox-2, OPN, hCG, Utf-1 and INF $\tau$ . variation in the level of Oct-4 expression by as little as 30% has been shown to maintain cells either in the totipotent state or to drive embryonic stem cells into 15 differentiation.

Two remarkable characteristics of MCTs are 3D-colony growth and the ability to grow in suspension. Our data provides convincing evidence that unlike many cell lines 20 derived from tumours or cells transformed by oncogenic agents, the MCT subpopulation does not result from spontaneous immortalisation or transformation. MCTs do not exhibit a crisis followed by clonal outgrowth and chromosomal abnormalities or aneuploidies, and show 25 reversibility of the altered growth characteristics after exposure to standard cell culture conditions.

#### EXPERIMENTAL PROTOCOL

##### 30 CELL CULTURE OF FETAL AND ADULT FIBROBLASTS

Primary fibroblasts were prepared by enzymatic isolation of eviscerated fetuses<sup>9</sup> or by mesenchymal explant (<1mm<sup>3</sup>) cultures of connective tissue pasted to the dish surface 35 by employing recalcified microdrops of bovine plasma and maintained in Dulbeccos Modified Eagles Medium (DMEM) medium supplemented with 1mM glutamine, 1% non-essential

amino acids 1% vitamin solution, 0.1 mM mercaptoethanol, 100U/ml penicillin, 100 mg/ml streptomycin (all from Sigma, Deisenhofen, Germany), containing 10% FCS from selected batches (Gibco, Karlsruhe, Germany, batch numbers 5 40G321K, 40G2810K) and incubated in a humidified 95% air/5% CO<sub>2</sub> atmosphere at 37°C. Outgrowing cells were trypsinised and subpassaged once prior to cryoconservation. For high serum culture the serum content of the standard medium was increased to 30% FCS. For 10 suspension culture, colonies were selectively isolated and completely dissociated in a trypsin solution, then 10<sup>4</sup> cells were seeded into bacteriological dishes (35 mm). Every second day 50% of the medium was replaced with new medium. To determine the maximal replicative limit, 15 cultures were serially subpassaged and 12.5 x 10<sup>3</sup> cells were seeded per cm<sup>2</sup> in 6-well-dishes, trypsinised after 5-7 days, counted and reseeded. The number of accumulated population doublings per passage was determined using the equation, PD = log (A/B) / log2, in which A is the number 20 of collected cells and B is the number of plated cells. Murine fibroblasts were obtained from day 11.5-14.5 fetuses or adult animals of OG2 mice homozygous for a Oct4-GFP transgene. Confocal microscopy was applied to detect GFP using a Zeiss Axiomat LSM and an excitation wavelength 25 of 488 nm. ES cells (wild type GS1 129/Sv) were cultured as described previously.

RT-PCR DETECTION OF OCT4 AND eGFP mRNAs

30 In brief, total RNA was isolated from cells grown in 6-well dishes and reverse transcribed into cDNA using random hexamers as primers. Murine Oct4 and GFP cDNAs were amplified by PCR with the following primers and conditions:

35 5'-GGC GTT CTC TTT GGA AAG GTG TTC, and  
5'-CTC GAA CCA CAT CC TTC TCT

(35 cycles, annealing temperature 57°C) for the murine  
Oct4:

5 5'-TGA CCC TGA AGT TCA TCT GC and  
5'-TGA AGT TCA CCT TGA TGC CG

(35 cycles) for GFP. Porcine Oct4 was amplified with:

10 5'-AGGTGTTCAGCCAAACGACC and  
5'-TGATCGTTGCCCTCTGGC

primers (AJ251914) and 36 cycles. The PCR reactions were  
performed in 20 µl volumes, consisting of 20 mM Tris.HCl  
15 (pH 8.4), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 200 µM dNTPs, 1 µM of  
specific primer pairs and 0.5 units of Taq DNA polymerase  
(Gibco).

MEASUREMENT OF CELL PROLIFERATION BY BRDU INCORPORATION

20 DNA synthesis was measured by 5-bromo-2' deoxy-uridine  
(BrdU) incorporation as described. Incorporated BrdU was  
detected by a chromogenic immunoassay employing an anti-  
BrdU antibody conjugated with alkaline phosphatase.

25 IMMUNOHISTOLOGY

Cells grown on gelatinised coverslips, were fixed in cold  
80% methanol. The following monoclonal antibody dilutions  
30 were used: anti-vimentin (AMF-17b, 1:200) (Developmental  
Studies Hybridoma Bank, Iowa) and anti-cytokeratin  
(peptide17, 1:100, Sigma). A rhodamine-labelled secondary  
anti-mouse antibody (1:2000, Molecular Probes, NL) was  
used. In some cases the nuclei were counterstained with 1  
35 mM Hoechst 33342<sup>37</sup>. The samples were examined with an  
Olympus BX60 microscope equipped with phase-contrast and  
epifluorescence optics, using band-pass rhodamine and

Hoechst filter sets.

STAINING OF ENDOGENOUS ALKALINE PHOSPHATASE ACTIVITY

- 5 Cell cultures were washed with PBS, fixed in 3.7 % paraformaldehyde for 15 minutes, washed in PBS and then incubated in a solution containing 25 mM TrisHC pH 9.0, 4mM MgCl<sub>2</sub>, 0.4 mg/ Na- $\alpha$ -naphthylphosphate, 1 mg/ml Fast Red TR (Sigma) and 0.05% Triton X-100 for 60 minutes.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for selective culturing of primary cell cultures comprising culturing tissue biopsies in the presence of at least 25% serum relative to the amount of culture medium.

5

Dated this 17th day of October 2003  
10 CRC FOR INNOVATIVE DAIRY PRODUCTS

15 By their Patent Attorneys  
GRIFFITH HACK  
Fellows Institute of Patent and  
Trade Mark Attorneys of Australia




FIGURE 1

2/6







FIGURE 2




**FIGURE 3**



**FIGURE 4**

**FIGURE 5**

6/6



**FIGURE 6**

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/AU04/001408

International filing date: 15 October 2004 (15.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: AU  
Number: 2003905692  
Filing date: 17 October 2003 (17.10.2003)

Date of receipt at the International Bureau: 08 November 2004 (08.11.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**